Suppr超能文献

无创通气(NIV)在慢性阻塞性肺疾病(COPD)急性加重期管理中的作用:一项系统评价

Role of Non-invasive Ventilation (NIV) in Managing Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review.

作者信息

Abualhamael Shahad Abduljalil, Alasmi Ahmed T, Alqurayqiri Abdulrahman F, Alzahrani Abdulillah A, Alsehli Ahmed D, Althikra Abdulaziz H, Alsadi Safwan O, Almaghrabi Mussab Z, Alhamdi Turki S, Alsehli Meshal D

机构信息

Department of Internal Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.

Department of Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.

出版信息

Cureus. 2024 Aug 21;16(8):e67418. doi: 10.7759/cureus.67418. eCollection 2024 Aug.

Abstract

Chronic obstructive pulmonary disease (COPD) is a significant global health issue that is characterized by airflow constriction and breathing difficulties. Non-invasive ventilation (NIV) is a recommended treatment for acute exacerbations of COPD (AECOPD), offering benefits over invasive mechanical ventilation (IMV). We aimed to evaluate the effectiveness, safety, and impact of NIV in managing AECOPD. The study adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched PubMed, Medline, Cochrane Library, Embase, and Google Scholar for relevant studies published between 2015 and 2024. Inclusion criteria focused on studies involving AECOPD patients treated with NIV, including randomized controlled, cohort, and observational studies. We included 10 studies that fit our inclusion criteria for a thorough review. From the studies selected, NIV demonstrated significant reductions in mortality rates, intubation rates, and hospital stays compared to IMV. Albeit the need to train healthcare providers is essential, high adherence to NIV guidelines was observed. Different NIV modes showed comparable efficacy, and structured weaning protocols reduced relapse rates. NIV is a highly effective and safe treatment for patients with AECOPD than IMV. High-flow nasal therapy (HFNT) is a viable alternative for patients intolerant to NIV. Further research should standardize treatment protocols and optimize NIV use in clinical practice.

摘要

慢性阻塞性肺疾病(COPD)是一个重大的全球健康问题,其特征为气流受限和呼吸困难。无创通气(NIV)是慢性阻塞性肺疾病急性加重期(AECOPD)的推荐治疗方法,相较于有创机械通气(IMV)具有优势。我们旨在评估无创通气在管理AECOPD方面的有效性、安全性和影响。该研究遵循系统评价和Meta分析的首选报告项目(PRISMA)指南。我们在PubMed、Medline、Cochrane图书馆、Embase和谷歌学术上搜索了2015年至2024年发表的相关研究。纳入标准侧重于涉及接受无创通气治疗的AECOPD患者的研究,包括随机对照、队列和观察性研究。我们纳入了10项符合纳入标准的研究进行全面综述。从所选研究来看,与有创机械通气相比,无创通气在死亡率、插管率和住院时间方面有显著降低。尽管培训医疗保健提供者很有必要,但观察到对无创通气指南的高依从性。不同的无创通气模式显示出相当的疗效,结构化的撤机方案降低了复发率。对于AECOPD患者,无创通气比有创机械通气是一种更高效、安全的治疗方法。高流量鼻导管治疗(HFNT)是不耐受无创通气患者的一种可行替代方案。未来的研究应规范治疗方案并优化无创通气在临床实践中的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/953c/11415004/0f97a8b5bcc2/cureus-0016-00000067418-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验